The United States Food and Drug Administration (USFDA) has completed inspection at Sequent Scientific’s manufacturing facility situated at Visakhapatnam, Andhra Pradesh between September 18, 2023 and September 22, 2023. At the end of the inspection, the company has been issued a Form 483 with one observation. The observation is procedural in nature. The company will respond to the USFDA within the stipulated timeline and work closely with them to address the observation at the earliest.
Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals.
